Evidence map›Paper›PMID 33708035›Full record

ArticleAdvanced functional materials2021

siRNA nanoparticle suppresses drug-resistant gene and prolongs survival in an orthotopic glioblastoma xenograft mouse model.

Kui Wang, Forrest M Kievit, Peter A Chiarelli, Zachary R Stephen, Guanyou Lin, John R Silber, Richard G Ellenbogen, Miqin Zhang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kui WangDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, United States.
Forrest M KievitDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, United States.
Peter A ChiarelliDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, United States.
Zachary R StephenDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, United States.
Guanyou LinDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, United States.
John R SilberDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, United States.
Richard G EllenbogenDepartment of Neurological Surgery, University of Washington, Seattle, WA 98195, United States.
Miqin ZhangDepartment of Materials Science and Engineering, University of Washington, Seattle, WA 98195, United States; Department of Neurological Surgery, University of Washington, Seattle, WA 98195, United States.
University of Washington · USChildren's Hospital of Los Angeles · USUniversity of Nebraska–Lincoln · US

Funding

Iron oxide nanotheranostics for breast cancerR01EB026890 · NIBIB · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2018 to 2021
$1.9M
Multifunctional nanoparticles to improve treatment of human glioblastomaR01CA161953 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2013 to 2017
$1.7M
Nanotechnology and Physical Science Training Program in Cancer ResearchT32CA138312 · NCI · UNIVERSITY OF WASHINGTON · PI ZHANG, MIQIN · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA161953NCI NIH HHS T32 CA138312NIBIB NIH HHS R01 EB026890
6 · The paper itself

Abstract

Temozolomide (TMZ) is the standard of care chemotherapy drug for treating glioblastomas (GBMs), the most aggressive cancer that affects people of all ages. However, its therapeutic efficacy is limited by the drug resistance mediated by a DNA repair protein, O

Indexed as

Brain tumordrug resistanceGBM stem cellnano drug carriersnanoparticleO6-methylguanine-DNA methyltransferasesiRNA deliverytreatment resistance

Identifiers

PMID33708035
PMCPMC7942690
OpenAlexW3096041557

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.